Marker Therapeutics lands $2.6M FDA grant for pancreatic cancer therapy
What's the deal? Marker TherapeuticsDealroom has a profile for this one. Try Dealroom → has won a $2.6 million grant from the US Food and Drug Administration's Orphan Products Development programDealroom has a profile for this one. Try Dealroom → to fund a Phase 1 study of MT-601, its investigational MAR-T cell therapy for locally advanced unresectable pancreatic cancer. The company disclosed the award in an October 2026 filing.
Why it matters: The FDA selected six projects from 66 applications for its fiscal year 2026 orphan-products grants, making the award a competitive validation. It is also non-dilutive — funding that does not require issuing new shares.
Context: The grant adds to prior non-dilutive support for the MT-601 program, including a $2 million NIHDealroom has a profile for this one. Try Dealroom → grant and a $9.5 million award from Texas's CPRIT, of which Marker says it has received only part.
What's the endgame? The money supports a company-sponsored Phase 1 study expected to start in Q1 2027. Marker aims to build on earlier findings with expanded antigen targeting, higher T-cell doses, and lymphodepletion.
What could go wrong? A Baylor-led Phase 1/2 study reported an 84.6% disease-control rate and median overall survival of 14.1 months. Those results are encouraging but do not establish MT-601's efficacy in a larger trial, and the grant is not an FDA endorsement.
The signal: For a small-cap biotech, stacking non-dilutive grants is a way to advance a pipeline without tapping shareholders. The award keeps MT-601 moving toward a pivotal test in one of oncology's hardest-to-treat indications.
Read more: kalkinemedia.com
Image credit: Marker Therapeutics
